PT-141 – 10mg: A Potent Sexual/Libido Enhancing Peptide Through the Brain
Bremelanotide, commonly known as PT-141, is a synthetic peptide medication used to treat Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. It is FDA-approved under the brand name Vyleesi and works by stimulating sexual desire through the central nervous system rather than affecting blood flow.
Unlike traditional erectile dysfunction medications that act on the vascular system, Bremelanotide targets brain pathways involved in sexual arousal. Learn more about this aphrodisiac sexually stimulating peptide in our blog post here.
What Is PT-141 (Bremelanotide)?
PT-141 is a melanocortin receptor agonist that activates specific receptors in the brain—primarily MC3R and MC4R—to enhance sexual desire and arousal. Because it works neurologically rather than vascularly, it represents a different treatment approach compared to PDE5 inhibitors such as sildenafil.
FDA-Approved Uses of Bremelanotide
Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Bremelanotide is FDA-approved for the treatment of Generalized Acquired Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. HSDD is characterized by:
Persistent lack of sexual desire
Personal distress related to low libido
Symptoms not attributable to another medical or psychiatric condition
Off-Label Uses of PT-141
Although not FDA-approved for men, PT-141 is sometimes prescribed off-label for:
Erectile dysfunction (ED)
Libido enhancement
Sexual performance support
Off-label use should always be supervised by a qualified healthcare provider.
How Bremelanotide Works
Unlike medications that increase blood flow to the genital area, Bremelanotide:
Stimulates melanocortin receptors (MC3R and MC4R) in the brain
Enhances sexual arousal signaling
Works independently of nitric oxide pathways
Because it acts centrally, it may be beneficial for individuals whose low libido is not primarily vascular in origin.
Administration and Onset of Action
Delivery Method: Subcutaneous injection (best method)
Injection Site: Thigh or abdomen
Timing: Typically administered 30–60 minutes before anticipated sexual activity
Onset: Effects are generally experienced within 30 to 60 minutes
It is not intended for daily use and should only be used as directed by a healthcare provider.
Common Side Effects of PT-141
The most commonly reported side effects include:
Nausea (most frequent)
Flushing
Headache
Vomiting
Dizziness
Some individuals may also experience temporary increases in blood pressure.
Safety Considerations
Bremelanotide is not recommended for:
Men (for FDA-approved use)
Postmenopausal women
Individuals with uncontrolled high blood pressure
Patients with cardiovascular disease
It is also not indicated for HSDD caused by:
Relationship issues
Psychiatric disorders
Medication side effects
Other underlying medical conditions
Proper evaluation is essential before starting treatment.
PT-141 vs. Traditional ED Medications
| Feature | Bremelanotide (PT-141) | PDE5 Inhibitors (e.g., Sildenafil) |
|---|---|---|
| Primary Target | Brain (CNS) | Blood vessels |
| Mechanism | Melanocortin receptor activation | Nitric oxide pathway |
| Libido Enhancement | Yes | Primarily improves erection quality |
| FDA-Approved For | HSDD in premenopausal women | Erectile dysfunction |
Is Bremelanotide Right for You?
Bremelanotide offers a unique, brain-based approach to treating low sexual desire. Because sexual health is complex and influenced by multiple factors, consultation with a licensed healthcare provider is essential for proper diagnosis and personalized treatment planning.
What Can I Learn More?
1. Mechanism of action (neurobiology)
- The neurobiology of bremelanotide for sexual desire
- Explains how PT-141 works via melanocortin receptors (MC4R) in the brain to influence sexual desire and dopamine release.
2. Phase 3 clinical trials (human evidence)
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder
- Large randomized trials showing significant improvements in sexual desire and reduced distress in women vs placebo.
3. Erectile dysfunction clinical study (men)
- Double-blind placebo-controlled evaluation of PT-141
- Demonstrated statistically significant erectile responses compared to placebo, with good tolerability.
4. Foundational PT-141 research paper
- PT-141: a melanocortin agonist for sexual dysfunction
- Early research showing dose-dependent increases in erectile activity in both healthy men and ED patients.
Common Stacks & Related Peptides
PT-141 is not commonly stacked with any other peptide as it is generally an on-demand use peptide only. It is, however, related to Melanotan II. PT-141 is a metabolite of Melanotan II developed specifically for its effects on sexual function without significant pigmentation activity. PT-141 and Melanotan II are both synthetic cyclic peptide analogues that act on melanocortin receptors, particularly MC3R and MC4R in the central nervous system. Melanotan II stimulates melanin production in skin cells (melanocytes) while also activating central pathways involved in sexual arousal, while PT-141 only affects sexual function without the melanin activity. PT-141 is widely used in the sexual performance category amongst adult researchers.
